Events & Presentations

Upcoming & Recent Events

H.C. Wainwright 21st Annual Global Investment Conference
New York, NY – September 8-10 2019 – Webcast – Slides

European Society of Cardiology(ESC)
Paris, France – Saturday 31 August - Wednesday 4 September 2019 – Poster – In a 36-Week Placebo Controlled Phase 2 Trial in Patients with Non-alcoholic Steatohepatitis (NASH), Treatment with MGL-3196 (resmetirom) Significantly Reduces Atherogenic Lipoprotein Particles.

Presentations

Non-Confidential Company Presentation

LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone receptor beta selective agonist, in a 12 week study in HeFH patients
August 21, 2018

MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
October 20-24, 2017

MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study

Archived Events

5th Paris NASH meeting
Paris, France – July 11, 2019

JMP Securities Life Sciences Conference
New York, NY – June 19 – 20, 2019

Goldman Sachs 40th Annual Global Healthcare Conference
Rancho Palos Verdes, CA – June 11 - 13, 2019

Jefferies 2019 Global Healthcare Conference
New York, NY – June 4 - 7

UBS 2019 Global Healthcare Conference
New York, NY – May 20 – 22, 2019

3rd Annual NASH Summit
Boston, MA – April 22-25 2019

International Liver Congress™ 2019, European Association for the Study of the Liver (EASL)
Vienna – April 11, 2019

Roth NASH Investor Conference
New York, NY – March 28, 2019

More Archived Events …

Oppenheimer Healthcare Conference
New York, NY – March 19 – 20, 2019

Roth Conference
Laguna Niguel, CA – March 17 – 19, 2019

Cowen Healthcare Conference
Boston, MA – March 11 – 13, 2019

NASH-TAG 2019 Conference
Park City, UT – January 3 – 5, 2019

Citi Global Healthcare Conference
New York, NY – December 5–6, 2018

3rd Annual World Preclinical Congress
Lisbon, Portugal – November 27–30, 2018

Evercore ISI 2018 HealthConX Conference
Boston, MA – November 27, 2018

Evercore ISI Madrigal
Webinar – November 19, 2018

Credit Suisse Annual Healthcare Conference
Scottsdale, AZ – November 14, 2018

AASLD – The Liver Meeting 2018 – Analyst/Investor KOL Event
San Francisco, CA – November 12, 2018

AASLD – The Liver Meeting 2018 – Plenary Presentation
San Francisco, CA – November 12, 2018

NASH Summit Europe 2018
Frankfurt, Germany – October 22–24, 2018

Roth NASH Investor Conference
New York, NY – October 17, 2018

H. C. Wainwright 20th Annual Global Investment Conference
New York, NY – September 4-6, 2018

JMP Securities Life Sciences Conference
New York, NY – June 21, 2018

Goldman Sachs 39th Annual Global Healthcare Conference
Rancho Palos Verdes, California – June 13, 2018

Review of Madrigal’s 36-week phase 2 results for MGL-3196
New York, NY – May 31, 2018 8:30am

EASL International Liver Congress 2018
Paris, France – April 11-15, 2018

HC Wainwright NASH Investor Conference 2018
New York, NY – March 19, 2018

The Cowen and Company 38th Annual Health Care Conference
Boston, MA – March 14th 2018

Global NASH Congress
London, UK – February 26-27, 2018

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
Conference Call & Webcast – February 8th, 2018

2018 NASH-TAG CONFERENCE
Thyroid Hormone Receptor Agonist – Becky Taub, MD
Park City, Utah – January 4-6, 2018

Madrigal Announces Top-line Results from Phase 2 NASH Clinical Trial
Conference Call & Webcast – December 6 2017 8:30 am ET

Evercore ISI Biopharma Catalyst/Deep Dive Conference
Boston, MA – November 29-30, 2017

Jefferies 2017 London Healthcare Conference
London, UK – November 15-16, 2017

FIRST EASL NAFLD SUMMIT
Vitamin D, thyroid function (the obvious and neglected; including Liver-Directed Thyroid Hormone Receptor-β (THR-β) agonists
Rome, Italy – November 9-11, 2017

AASLD Liver Meeting
Poster # 1969: MGL-3196, a β-Selective Thyroid Hormone Receptor (THR) Agonist, Demonstrates Metabolic, Anti-inflammatory and Anti-fibrotic Benefits in a Long-term High Fat Diet (HFD) Mouse NASH Model
Washington, DC – October 20-24, 2017

Discovery on Target Conference:
Thyroid Hormone Receptor Targets
Boston, MA – September 26, 2017

Cantor Fitzgerald Healthcare Conference
New York, NY – September 25-27, 2017

HC Wainwright / Rodman & Renshaw Annual Healthcare Conference
New York, NY – September 10-12, 2017

JMP Securities Life Sciences Conference
New York, NY – June 20-21, 2017

Jefferies 2017 Healthcare Conference
New York, NY – June 6-9, 2017

Jefferies 2018 Global Healthcare Conference
New York, NY – June 5-8, 2018

H.C. Wainwright NASH Investor Conference
New York, NY – April 3, 2017

ROTH Investor Conference
Laguna Niguel, CA – March 13, 2017

Cowen Healthcare Conference
Boston, MA – March 8, 2017